John Diekman Net Worth & Insider Trades

John Diekman Audentes Therapeutics, Inc

As of April 26, 2017

What is John Diekman's Net Worth?

The current estimated net worth of Audentes Therapeutics, Inc's John Diekman is estimated to be about $184.54M . John Diekman owns about 2,500,113 units of Audentes Therapeutics, Inc common stock. Recently at Audentes Therapeutics, Inc, John Diekman has sold an estimated value of $0 worth.

What is John Diekman's Past Insider Trading?

John Diekman's largest purchase order was 172,413 units , worth over $2.5M on April 26, 2017. In total, John Diekman has made about 1 transaction recently at Audentes Therapeutics, Inc. John Diekman usually trades in April, with the busiest year in 2017.

AM Partners III LLC, AM CoInvestors III LP, AM VENTURES III LP, JOHN DIEKMAN, Andrew J Schwab, SCOTT ROCKLAGE

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is John Diekman's' Mailing Address?

  • Mailing address is C/o 5 Am Ventures 3000 Sand Hill Rd Menlo Park CA 94025 CA

What are Audentes Therapeutics, Inc's Past Insider Trades?

Audentes Therapeutics, Inc's most recent insider trade came on December 27, 2019 by Louis Lange M.D., Ph.D. who sold 11,000 units worth $655.59K . In the last 3 years, insiders at Audentes Therapeutics, Inc have sold an estimated value of $142.4M and bought an estimated value of $15.46M worth of shares. Insider trading is most common in January, with the busiest year in 2017. The most active traders at the company are Matthew Patterson, Chief Executive Officer,  Louis G Lange, Director,  and Suyash Prasad, Senior VP & Chief Med Officer .

Audentes Therapeutics, Inc. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1